Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3,358 Comments
1,997 Likes
1
Anthani
Insight Reader
2 hours ago
Couldβve made use of this earlier.
π 174
Reply
2
Amareion
Power User
5 hours ago
Really wish I had known before.
π 200
Reply
3
Nhoa
Elite Member
1 day ago
Missed the notice⦠oof.
π 232
Reply
4
Mbene
Senior Contributor
1 day ago
If only I had spotted this sooner.
π 135
Reply
5
Royesha
Influential Reader
2 days ago
Ah, what a pity I missed this.
π 300
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.